Comparison
3 Methylglutaconic Aciduria Type Viia C5676967 vs 17q11 2 Microduplication Syndrome C3495679
Clinical comparison between 3 Methylglutaconic Aciduria Type Viia and 17q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type Viia C5676967
A rare inherited metabolic disorder affecting mitochondrial function. It typically appears in infancy with developmental delay, movement problems, and muscle weakness. Management focuses on supportive care and addressing specific symptoms.
17q11 2 Microduplication Syndrome C3495679
A genetic disorder caused by duplication of a segment on chromosome 17. Individuals may have developmental delays, behavioral concerns, and physical features. Treatment focuses on early intervention.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type Viia C5676967
0-2
17q11 2 Microduplication Syndrome C3495679
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type Viia C5676967
severe
17q11 2 Microduplication Syndrome C3495679
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type Viia C5676967
Chronic
17q11 2 Microduplication Syndrome C3495679
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type Viia C5676967
No
17q11 2 Microduplication Syndrome C3495679
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type Viia C5676967
metabolic
17q11 2 Microduplication Syndrome C3495679
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type Viia C5676967
metabolic
17q11 2 Microduplication Syndrome C3495679
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-viia-C5676967 and 17q11-2-microduplication-syndrome-C3495679 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type Viia C5676967 | 17q11 2 Microduplication Syndrome C3495679 | Discriminating power |
|---|---|---|---|
| Developmental delay | Typically begins in infancy and may accompany movement problems and weakness. | May occur with behavioral concerns and variable physical features. | Moderate |
| Movement and muscle weakness | Described as typical, reflecting mitochondrial dysfunction. | Not established from the supplied description. | High |
| Behavioral concerns | Not specifically established. | May be present and are a focus of early intervention. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type Viia C5676967 when
Infantile delay with movement problems and weakness
This pattern matches the described metabolic presentation.
Moderate
Suspected mitochondrial metabolic disorder
The condition is classified as an inherited metabolic disease.
High
Severe chronic course
Supplied severity is severe, but individual prognosis remains uncertain.
Moderate
Choose 17q11 2 Microduplication Syndrome C3495679 when
Delay with behavioral and physical features
These are the features described for the chromosomal condition.
Moderate
Confirmed 17q11.2 duplication
The diagnosis depends on the chromosomal finding and clinical interpretation.
High
Need for developmental early intervention
Management is described as supportive and intervention-focused.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type Viia C5676967 | 17q11 2 Microduplication Syndrome C3495679 | Interpretation |
|---|---|---|---|
| Urine organic acid analysis | May support 3-methylglutaconic aciduria; no cutoff is supplied. | No characteristic metabolic result is established. | An abnormal result is not itself a complete diagnosis. |
| Chromosomal microarray | Not the defining test in the supplied data. | May identify duplication at 17q11.2. | Genetic findings require clinician correlation. |
| Neurologic and developmental assessment | May document weakness, movement problems, and delay. | May document delay, behavior, and functional needs. | Assessment guides care but does not establish etiology alone. |
Prognosis comparison
3 Methylglutaconic Aciduria Type Viia C5676967
- Outcome
- Severe chronic course is described, but survival and functional outcome are not established.
- Factors
- Age at onset, neurologic involvement, and response to supportive care may matter.
17q11 2 Microduplication Syndrome C3495679
- Outcome
- Moderate chronic course is described, with variable developmental and behavioral impact.
- Factors
- Duplication findings, developmental profile, and access to intervention may matter.
Time frame: Both may begin early and require long-term follow-up; exact timelines are unavailable.
Individual prognosis cannot be inferred from these labels alone.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Movement problems and weakness may cause substantial disability. Developmental impairment may occur; motor severity is not established. Extent varies and is not quantified here. |
| Learning or behavioral difficulty | Possible with developmental delay, but behavior is not specifically described. Behavioral concerns are explicitly described. Needs should be assessed individually. |
| Long-term care needs | Severe chronic disease may require ongoing supportive care. Moderate chronic condition may require early and ongoing intervention. No mortality or complication rates are supplied. |
Patient education highlights
- HighDifferent causes
One is a mitochondrial metabolic disorder; the other is a chromosomal duplication. Neither is communicable.
- HighSupportive care
No disease-specific dose or cure is established here; care targets symptoms and development.
- MediumSpecialist review
Genetic, metabolic, neurologic, and developmental specialists should interpret results and plans.